Holen Sie sich die Stockscreener-App
4.38
2.34%
0.10
Handel nachbörslich:
4.39
0.010
+0.23%
Schlusskurs vom Vortag:
$4.28
Offen:
$4.41
24-Stunden-Volumen:
2.54M
Relative Volume:
0.46
Marktkapitalisierung:
$1.52B
Einnahmen:
$62.90M
Nettoeinkommen (Verlust:
$-204.63M
KGV:
-7.3037
EPS:
-0.5997
Netto-Cashflow:
$-181.78M
1W Leistung:
+2.34%
1M Leistung:
-21.22%
6M Leistung:
+45.51%
1J Leistung:
+125.77%
1-Tages-Spanne:
$4.365
$4.47
1-Wochen-Bereich:
$4.125
$4.47
52-Wochen-Spanne:
$1.54
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Firmenname
Nuvation Bio Inc
Sektor
Branche
Telefon
332-208-6102
Adresse
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
4.38 | 1.49B | 62.90M | -204.63M | -181.78M | -0.5997 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-19 | Eingeleitet | B. Riley Securities | Buy |
| 2025-09-30 | Eingeleitet | Jefferies | Buy |
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-03-27 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-26 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-01-06 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-03-08 | Eingeleitet | BTIG Research | Buy |
| 2021-03-08 | Eingeleitet | Cowen | Outperform |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Nuvation Bio Inc Aktie (NUVB) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio ... - Bluefield Daily Telegraph
2026-03-24 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nuvation Bio Inc. (NUVB) And Encourages Investors to Reach Out | NYSE:NUVB | Press Release - Stockhouse
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Swings - Yahoo Finance
Bullish analyst sentiment on Nuvation Bio (NUVB) amid early commercialization progress - MSN
Bullish Analyst Sentiment on Nuvation Bio (NUVB) Amid Early Commercialization Progress - Insider Monkey
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Swings? - simplywall.st
5 Most Active Penny Stocks to Buy - Insider Monkey
Nuvation Bio Cancer Data Update Tests Valuation Gap After Share Pullback - Sahm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc.NUVB - PR Newswire
Nuvation Bio Inc. (NUVB) is a Buy at H.C. Wainwright on Cancer Drug Development Progress - MSN
Nuvation Bio (NYSE:NUVB) Expands Cancer Story With Strong Update Nyse Composite Today - Kalkine Media
New Highs: Will Nuvation Bio Inc outperform the market in YEARWeekly Investment Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Nuvation Bio set to present efficacy and safety results of ROS1 inhibitor at AACR26 - Traders Union
Lung cancer drug IBTROZI keeps responses going over 4 years in trial - Stock Titan
Nuvation Bio (NUVB) Is Down 6.1% After Eisai Deal And Stock Shelf Filing Has The Bull Case Changed? - simplywall.st
Nuvation Bio Inc. (NUVB) announces exclusive licensing agreement with Eisai to expand global reach of taletrectinib - MSN
Nuvation Bio Inc. (NYSE:NUVB) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm - marketscreener.com
RBC Capital Lifts PT on Nuvation Bio (NUVB) to $13 From $12 – Here’s Why - Insider Monkey
15 Best Penny Stocks to Buy According to Reddit - Insider Monkey
Nuvation Bio (NUVB) Q4 2025 Earnings Transcript - AOL.com
A Look At Nuvation Bio (NUVB) Valuation After Its 2025 Results Show Revenue Growth And A Narrowed Net Loss - simplywall.st
NUVB: IBTROZI leads in ROS1 lung cancer with rapid uptake, superior efficacy, and expanding indications - TradingView
NUVB: Ibtrozi leads ROS1 market growth with superior efficacy and expanding first-line adoption - TradingView
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PayPal Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – PYPL - GlobeNewswire Inc.
Aug Setups: Will Nuvation Bio Inc outperform the market in YEARLayoff News & Daily Profit Focused Screening - baoquankhu1.vn
Nuvation Bio Earnings Call: IBTROZI Surge, Long Runway - The Globe and Mail
Nuvation Bio Faces Weak Start with 18.49% Gap Down Amid Market Concerns - Markets Mojo
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact L - GuruFocus
Nuvation Bio Inc. Q4 2025 Earnings Call Summary - finance.yahoo.com
Citigroup Inc. Has $3.42 Million Stake in Nuvation Bio Inc. $NUVB - MarketBeat
Truist Highlights Nuvation Bio’s (NUVB) Ibtrozi’s Robust Market Uptake and Lead Over Competitors - MSN
Nuvation Bio Stock Hits Day Low of $4.16 Amid Price Pressure - Markets Mojo
Nuvation Bio Hits Day High with Strong 8.72% Intraday Surge - Markets Mojo
Q1 EPS Estimates for Nuvation Bio Reduced by HC Wainwright - MarketBeat
Nuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks - The Globe and Mail
10 Best Low Cost Stocks to Buy Under $5 - Insider Monkey
Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch - Bitget
NUVB: First-line patient growth, strong efficacy, and robust cash position drive positive outlook - TradingView
Nuvation Bio Inc. (NYSE:NUVB) Q4 2025 Earnings Call Transcript - Insider Monkey
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - marketscreener.com
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out - GlobeNewswire
Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress - Yahoo Finance
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Malaysian Reserve
Finanzdaten der Nuvation Bio Inc-Aktie (NUVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):